Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 5, 2015, Pages 715-721

  Kwon, Yun Ju ^a   Kim, Hyun Ju ^a   Kim, Won Gon ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Antibacterial; Complestatin; Enoyl acyl carrier protein reductase; Fatty acid synthesis; Staphylococcus aureus

Indexed keywords

CD59 ANTIGEN; CHLORAMPHENICOL; CHLOROPEPTIN I; COMPLESTATIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE; FATTY ACID; NEUROPROTECTIN A; NORFLOXACIN; OLEIC ACID; OXACILLIN; OXIDOREDUCTASE; PALMITIC ACID; RIFAMPICIN; STEARIC ACID; TRICLOSAN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; CHLOROPHENOL; CYCLOPEPTIDE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENZYME INHIBITOR; OLIGOPEPTIDE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DNA SYNTHESIS; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GROWTH INHIBITION; IC50; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEIN SYNTHESIS; QUINOLONE RESISTANT STAPHYLOCOCCUS AUREUS; RNA SYNTHESIS; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG RESISTANCE; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; STREPTOMYCES;

ANTI-BACTERIAL AGENTS; CHLOROPHENOLS; DRUG RESISTANCE; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; FATTY ACIDS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; PEPTIDES, CYCLIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOMYCES;

EID: 84929572011     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00824     Document Type: Article

References (24)

1. Silver LL. Challenges of antibacterial discovery. Clin. Microbiol. Rev., 24, 71-109 (2011).
2. Heath RJ, Rock CO. Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs, 5, 146-153 (2004).
3. Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J. Biol. Chem., 281, 17541-17544 (2006).
4. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature, 394, 531-532 (1998).
5. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science, 279, 98-102 (1998).
6. Kaneko I, Kamoshida K, Takahashi S. Complestatin, a potent anti-complement substance produced by Streptomyces lavendulae. I. Fermentation, isolation and biological characterization. J. Antibiot. (Tokyo), 42, 236-241 (1989).
7. Singh SB, Jayasuriya H, Salituro GM, Zink DL, Shafiee A, Heimbuch B, Silverman KC, Lingham RB, Genilloud O, Teran A, Vilella D, Felock P, Hazuda D. The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. J. Nat. Prod., 64, 874-882 (2001).
8. Matsuzaki K, Ikeda H, Ogino T, Matsumoto A, Woodruff HB, Tanaka H, Omura S. Chloropeptins I and II, novel inhibitors against gp120-CD4 binding from Streptomyces sp. J. Antibiot. (Tokyo), 47, 1173-1174 (1994).
9. Tanaka H, Matsuzaki K, Nakashima H, Ogino T, Matsumoto A, Ikeda H, Woodruff HB, Omura S. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities. J. Antibiot. (Tokyo), 50, 58-65 (1997).
10. Kobayashi H, Shin-Ya K, Nagai K, Suzuki K, Hayakawa Y, Seto H, Yun BS, Ryoo IJ, Kim JS, Kim CJ, Yoo ID. Neuroprotectins A and B, bicyclohexapeptides protecting chick telencephalic neuronal cells from excitotoxicity. I. Fermentation, isolation, physico-chemical properties and biological activity. J. Antibiot. (Tokyo), 54, 1013-1018 (2001).
11. Kobayashi H, Shin-Ya K, Furihata K, Nagai K, Suzuki K, Hayakawa Y, Seto H, Yun BS, Ryoo IJ, Kim JS, Kim CJ, Yoo ID. Neuroprotectins A and B, bicyclohexapeptides protecting chick telencephalic neurons from excitotoxicity. II. Structure determination. J. Antibiot. (Tokyo), 54, 1019-1024 (2001).
12. Breazzano SP, Boger DL. Synthesis and stereochemical determination of complestatins A and B (neuroprotectins A and B). J. Am. Chem. Soc., 133, 18495-18502 (2011).
13. Zheng CJ, Sohn MJ, Lee S, Kim WG. Meleagrin, a New FabI Inhibitor from Penicillium chryosogenum with at least one additional mode of action. PLoS ONE, 8, e78922 (2013).
14. Zheng CJ, Yoo JS, Lee TG, Cho HY, Kim YH, Kim WG. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett., 579, 5157-5162 (2005).
15. Seto H, Fujioka T, Furihata K, Kaneko I, Takahashi S. Structure of complestatin, a very strong inhibitor of protease activity of complement in the human complement system. Tetrahedron Lett., 30, 4987-4990 (1989).
16. Shinohara T, Deng H, Snapper ML, Hoveyda AH. Isocomplestatin: total synthesis and stereochemical revision. J. Am. Chem. Soc., 127, 7334-7336 (2005).
17. Matsuzaki K, Ogino T, Sunazuka T, Tanaka H, Omura S. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I. J. Antibiot. (Tokyo), 50, 66-69 (1997).
18. Kaneko I, Fearon DT, Austen KF. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin. J. Immunol., 124, 1194-1198 (1980).
19. Nicolaou KC, Boddy CN, Brase S, Winssinger N. Chemistry, biology, and medicine of the glycopeptide antibiotics. Angew. Chem. Int. Ed. Engl., 38, 2096-2152 (1999).
20. Hubbard BK, Walsh CT. Vancomycin assembly: nature's way. Angew. Chem. Int. Ed. Engl., 42, 730-765 (2003).
21. Nagarajan R. Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J. Antibiot. (Tokyo), 46, 1181-1195 (1993).
22. Malabarba A, Strazzolini P, Depaoli A, Landi M, Berti M, Cavalleri B. Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. sp. VI. Chemical degradation: physico-chemical and biological properties of acid hydrolysis products. J. Antibiot. (Tokyo), 37, 988-999 (1984).
23. Pootoolal J, Thomas MG, Marshall CG, Neu JM, Hubbard BK, Walsh CT, Wright GD. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47934 from Streptomyces toyocaensis NRRL15009. Proc. Natl. Acad. Sci. U.S.A., 99, 8962-8967 (2002).
24. Chiu HT, Hubbard BK, Shah AN, Eide J, Fredenburg RA, Walsh CT, Khosla C. Molecular cloning and sequence analysis of the complestatin biosynthetic gene cluster. Proc. Natl. Acad. Sci. U.S.A., 98, 8548-8553 (2001).